Form 8-K - Current report:
SEC Accession No. 0001867096-26-000045
Filing Date
2026-06-11
Accepted
2026-06-11 07:16:14
Documents
14
Period of Report
2026-06-10
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20260610.htm   iXBRL 8-K 34777
2 EX-99.1 exh991exchangeofconvertibl.htm EX-99.1 11027
7 image_0a.jpg GRAPHIC 21439
  Complete submission text file 0001867096-26-000045.txt   226569

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20260610.xsd EX-101.SCH 2036
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20260610_def.xml EX-101.DEF 14916
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20260610_lab.xml EX-101.LAB 26174
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20260610_pre.xml EX-101.PRE 15570
17 EXTRACTED XBRL INSTANCE DOCUMENT xers-20260610_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 261081437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)